Literature DB >> 15497115

Anaplastic astrocytoma: diagnosis, prognosis, and management.

Siew Ju See1, Mark R Gilbert.   

Abstract

The designation of a tumor as anaplastic astrocytoma (AA) reflects a distinct histologic classification of malignant glioma characterized by an abundance of pleomorphic astrocytes with evidence of mitosis. Although these tumors are malignant, they have a better prognosis and a higher likelihood of response to treatment than glioblastoma. Despite advances in brain tumor imaging, making an accurate diagnosis requires the evaluation of tumor tissue and is essential for treatment planning. Currently, most patients undergo maximal surgical debulking of tumor followed by external beam radiation, often with subsequent adjuvant chemotherapy. However, despite the use of these treatment modalities, most tumors recur within a few years and these recurrent tumors are more refractory to subsequent therapies. This review examines the diagnosis, prognosis, and treatment of AAs. Ongoing clinical research investigations are also summarized, reflecting advances in our knowledge of the molecular pathogenesis of these tumors and providing hope for significant improvements in patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15497115     DOI: 10.1053/j.seminoncol.2004.07.004

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  24 in total

1.  Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma.

Authors:  Alba A Brandes; Linda Nicolardi; Alicia Tosoni; Marina Gardiman; Paolo Iuzzolino; Claudio Ghimenton; Michele Reni; Antonino Rotilio; Guido Sotti; Mario Ermani
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

2.  Influence of insurance status and income in anaplastic astrocytoma: an analysis of 4325 patients.

Authors:  Jacob Y Shin; Ja Kyoung Yoon; Aidnag Z Diaz
Journal:  J Neurooncol       Date:  2016-11-18       Impact factor: 4.130

3.  Anaplastic astrocytoma: prognostic factors and survival in 4807 patients with emphasis on receipt and impact of adjuvant therapy.

Authors:  Jacob Y Shin; Aidnag Z Diaz
Journal:  J Neurooncol       Date:  2016-07-11       Impact factor: 4.130

4.  Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas.

Authors:  Annick Desjardins; Jennifer A Quinn; James J Vredenburgh; Sith Sathornsumetee; Allan H Friedman; James E Herndon; Roger E McLendon; James M Provenzale; Jeremy N Rich; John H Sampson; Sridharan Gururangan; Jeannette M Dowell; August Salvado; Henry S Friedman; David A Reardon
Journal:  J Neurooncol       Date:  2007-01-24       Impact factor: 4.130

5.  MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression.

Authors:  Lei Chen; Xiang-Rong Chen; Run Zhang; Peng Li; Yi Liu; Ke Yan; Xiao-Dan Jiang
Journal:  J Neurooncol       Date:  2013-01-09       Impact factor: 4.130

6.  Predominant expression of OLIG2 over ID2 in oligodendroglial tumors.

Authors:  Shuji Mikami; Yuichi Hirose; Kazunari Yoshida; Takeshi Kawase; Akiko Ohnishi; Kazuo Nagashima; Makio Mukai; Yasunori Okada; Eiji Ikeda
Journal:  Virchows Arch       Date:  2007-03-13       Impact factor: 4.064

7.  Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Authors:  Annick Desjardins; David A Reardon; James E Herndon; Jennifer Marcello; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

8.  Downregulation of miR-383 promotes glioma cell invasion by targeting insulin-like growth factor 1 receptor.

Authors:  Zhanwen He; Danyang Cen; Xiangyang Luo; Dongfang Li; Pinggan Li; Liyang Liang; Zhe Meng
Journal:  Med Oncol       Date:  2013-04-06       Impact factor: 3.064

9.  Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Authors:  D A Reardon; A Desjardins; J J Vredenburgh; S Gururangan; J H Sampson; S Sathornsumetee; R E McLendon; J E Herndon; J E Marcello; J Norfleet; A H Friedman; D D Bigner; H S Friedman
Journal:  Br J Cancer       Date:  2009-11-17       Impact factor: 7.640

10.  Sequentially Programmed Magnetic Field Therapy in the Management of Recurrent Anaplastic Astrocytoma: A Case Report and Literature Review.

Authors:  V G Vasishta
Journal:  Case Rep Oncol       Date:  2010-06-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.